Cargando…

Survival of 48866 cancer patients: results from Nantong area, China

OBJECTIVE: This study aimed to provide a realistic observation of survival by major site for 48,866 cancer patients treated at a tertiary cancer hospital in a rural area of China. METHODS: Patients with cancer registered between 2007 and 2017 in the Nantong rural area were followed up. The starting...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Gao-Ren, Xu, Hong, Chen, Hai-Zhen, Chen, Yong-Sheng, Ni, Zhuo-Jian, Fan, Li-Yun, Zhang, Ai-Hong, Xu, Pei-Pei, Qian, Yun, Cai, Bo, Chen, Jian-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455932/
https://www.ncbi.nlm.nih.gov/pubmed/37637071
http://dx.doi.org/10.3389/fonc.2023.1244545
_version_ 1785096571782692864
author Wang, Gao-Ren
Xu, Hong
Chen, Hai-Zhen
Chen, Yong-Sheng
Ni, Zhuo-Jian
Fan, Li-Yun
Zhang, Ai-Hong
Xu, Pei-Pei
Qian, Yun
Cai, Bo
Chen, Jian-Guo
author_facet Wang, Gao-Ren
Xu, Hong
Chen, Hai-Zhen
Chen, Yong-Sheng
Ni, Zhuo-Jian
Fan, Li-Yun
Zhang, Ai-Hong
Xu, Pei-Pei
Qian, Yun
Cai, Bo
Chen, Jian-Guo
author_sort Wang, Gao-Ren
collection PubMed
description OBJECTIVE: This study aimed to provide a realistic observation of survival by major site for 48,866 cancer patients treated at a tertiary cancer hospital in a rural area of China. METHODS: Patients with cancer registered between 2007 and 2017 in the Nantong rural area were followed up. The starting date for survival calculation was the date of the first diagnosis of cancer at the Nantong Tumor Hospital, and the closing date was December 31, 2020. Observed survival (OS) was analyzed according to ICD-10 site, sex, age, region, and hospitalization period using the life table method and compared using the Wilcoxon (Gehan) statistic. RESULTS: The overall 5-year OS rate was 40.48% for all 48,866 patients, 30.19% for males, and 51.90% for females. The top five cancer sites, accounting for 60.51% of the total cases, were the esophagus, lung, stomach, liver, and cervix, with 5-year OS rates of 33.72%, 18.64%, 32.10%, 19.04%, and 71.51%, respectively. The highest 5-year OS was observed in the thyroid (87.52%) and the lowest was in the pancreas (6.37%). Survival was significantly higher in younger patients than in older patients, with 5-year OSs of 69.26% and 19.84% in those aged 20-29 and 90-99 years, respectively. Five-year OSs improved significantly from 39.35% in 2007-2011 to 41.26% in 2012-2017. CONCLUSION: Overall survival improved over the years, although the improvement at some sites was not significant. The observed survival varies from region to region, reflecting differences in the patterns of major sites, disparities in proportions of hospitalization, and demographic characteristics.
format Online
Article
Text
id pubmed-10455932
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104559322023-08-26 Survival of 48866 cancer patients: results from Nantong area, China Wang, Gao-Ren Xu, Hong Chen, Hai-Zhen Chen, Yong-Sheng Ni, Zhuo-Jian Fan, Li-Yun Zhang, Ai-Hong Xu, Pei-Pei Qian, Yun Cai, Bo Chen, Jian-Guo Front Oncol Oncology OBJECTIVE: This study aimed to provide a realistic observation of survival by major site for 48,866 cancer patients treated at a tertiary cancer hospital in a rural area of China. METHODS: Patients with cancer registered between 2007 and 2017 in the Nantong rural area were followed up. The starting date for survival calculation was the date of the first diagnosis of cancer at the Nantong Tumor Hospital, and the closing date was December 31, 2020. Observed survival (OS) was analyzed according to ICD-10 site, sex, age, region, and hospitalization period using the life table method and compared using the Wilcoxon (Gehan) statistic. RESULTS: The overall 5-year OS rate was 40.48% for all 48,866 patients, 30.19% for males, and 51.90% for females. The top five cancer sites, accounting for 60.51% of the total cases, were the esophagus, lung, stomach, liver, and cervix, with 5-year OS rates of 33.72%, 18.64%, 32.10%, 19.04%, and 71.51%, respectively. The highest 5-year OS was observed in the thyroid (87.52%) and the lowest was in the pancreas (6.37%). Survival was significantly higher in younger patients than in older patients, with 5-year OSs of 69.26% and 19.84% in those aged 20-29 and 90-99 years, respectively. Five-year OSs improved significantly from 39.35% in 2007-2011 to 41.26% in 2012-2017. CONCLUSION: Overall survival improved over the years, although the improvement at some sites was not significant. The observed survival varies from region to region, reflecting differences in the patterns of major sites, disparities in proportions of hospitalization, and demographic characteristics. Frontiers Media S.A. 2023-08-11 /pmc/articles/PMC10455932/ /pubmed/37637071 http://dx.doi.org/10.3389/fonc.2023.1244545 Text en Copyright © 2023 Wang, Xu, Chen, Chen, Ni, Fan, Zhang, Xu, Qian, Cai and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Gao-Ren
Xu, Hong
Chen, Hai-Zhen
Chen, Yong-Sheng
Ni, Zhuo-Jian
Fan, Li-Yun
Zhang, Ai-Hong
Xu, Pei-Pei
Qian, Yun
Cai, Bo
Chen, Jian-Guo
Survival of 48866 cancer patients: results from Nantong area, China
title Survival of 48866 cancer patients: results from Nantong area, China
title_full Survival of 48866 cancer patients: results from Nantong area, China
title_fullStr Survival of 48866 cancer patients: results from Nantong area, China
title_full_unstemmed Survival of 48866 cancer patients: results from Nantong area, China
title_short Survival of 48866 cancer patients: results from Nantong area, China
title_sort survival of 48866 cancer patients: results from nantong area, china
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455932/
https://www.ncbi.nlm.nih.gov/pubmed/37637071
http://dx.doi.org/10.3389/fonc.2023.1244545
work_keys_str_mv AT wanggaoren survivalof48866cancerpatientsresultsfromnantongareachina
AT xuhong survivalof48866cancerpatientsresultsfromnantongareachina
AT chenhaizhen survivalof48866cancerpatientsresultsfromnantongareachina
AT chenyongsheng survivalof48866cancerpatientsresultsfromnantongareachina
AT nizhuojian survivalof48866cancerpatientsresultsfromnantongareachina
AT fanliyun survivalof48866cancerpatientsresultsfromnantongareachina
AT zhangaihong survivalof48866cancerpatientsresultsfromnantongareachina
AT xupeipei survivalof48866cancerpatientsresultsfromnantongareachina
AT qianyun survivalof48866cancerpatientsresultsfromnantongareachina
AT caibo survivalof48866cancerpatientsresultsfromnantongareachina
AT chenjianguo survivalof48866cancerpatientsresultsfromnantongareachina